- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00354549
Bevacizumab and Erlotinib Followed by Cisplatin or Carboplatin and Gemcitabine in Treating Patients With Newly Diagnosed or Recurrent Stage IIIB or Stage IV NSCLC
Bevacizumab and Erlotinib First-Line Therapy in Advanced Non-Squamous Non-Small-Cell Lung Cancer (Stage IIIB/IV) Followed by Platinum-Based Chemotherapy at Disease Progression. A Multicenter Phase II Trial
RATIONALE: Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of tumor cells by blocking blood flow to the tumor. Erlotinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as cisplatin, carboplatin, and gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with erlotinib followed by cisplatin or carboplatin and gemcitabine at disease progression may be an effective treatment for non-small cell lung cancer.
PURPOSE: This phase II trial is studying how well giving bevacizumab together with erlotinib followed by cisplatin or carboplatin and gemcitabine works in treating patients with newly diagnosed or recurrent stage IIIB or stage IV non-small cell lung cancer.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
OBJECTIVES:
Primary
- Assess the efficacy of bevacizumab and erlotinib hydrochloride as initial therapy in patients with newly diagnosed or recurrent stage IIIB or IV non-squamous non-small cell lung cancer (NSCLC).
Secondary
- Assess the safety of bevacizumab and erlotinib hydrochloride as initial therapy in these patients.
- Assess the quality of life (QOL) in patients treated with bevacizumab and erlotinib hydrochloride.
- Assess the efficacy and safety of subsequent cisplatin or carboplatin in combination with gemcitabine hydrochloride in patients who have disease progression.
- Assess the QOL in patients treated with subsequent cisplatin or carboplatin in combination with gemcitabine hydrochloride at disease progression.
Tertiary
- Identify novel biomarkers in predicting response to therapy and toxicity in patients treated with bevacizumab and erlotinib hydrochloride as initial therapy.
OUTLINE: This is a multicenter, prospective, open-label study.
Patients receive bevacizumab IV over 90 minutes on day 1 and oral erlotinib hydrochloride once daily on days 1-21. Treatment repeats every 3 weeks in the absence of disease progression or unacceptable toxicity.
Beginning within 3 weeks of documented disease progression, patients receive gemcitabine hydrochloride IV over 30 minutes on days 1 and 8. They also receive cisplatin IV over 1 hour or carboplatin IV over 30 minutes on day 1. Treatment with gemcitabine hydrochloride with either cisplatin or carboplatin repeats every 21 days for up to 6 courses in the absence of disease progression or unacceptable toxicity.
Quality of life is assessed at baseline and periodically during study treatment.
After completion of study treatment, patients are followed every 3 months.
PROJECTED ACCRUAL: A total of 101 patients will be accrued for this study.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Basel, Switzerland, CH-4031
- Universitaetsspital-Basel
-
Bellinzona, Switzerland, CH-6500
- Oncology Institute of Southern Switzerland
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
DISEASE CHARACTERISTICS:
Histologically or cytologically confirmed non-squamous non-small cell lung cancer (NSCLC)
- Newly diagnosed or recurrent disease
Meets 1 of the following staging criteria:
Stage IIIB disease, meeting both of the following criteria:
- Proven malignant effusion or supraclavicular node involvement (i.e., N3 supraclavicular nodes)
- Not a candidate for curative multimodality treatment or surgery
- Stage IV disease
- Measurable disease, defined as ≥ 1 lesion (outside of irradiated areas) that can be measured in ≥ 1 dimension as ≥ 10 mm by spiral or multi-slice CT scan or MRI
- Immediate chemotherapy not clinically mandatory in the judgement of the investigator
- No intrathoracic large, centrally located tumors and/or cavitary lesions invading or abutting major blood vessels
No evidence of clinically active interstitial lung disease
- Patients with chronic stable radiographic changes who are asymptomatic are eligible
- No small cell lung cancer (SCLC), squamous NSCLC, or combined SCLC-NSCLC tumors
- No brain metastases
PATIENT CHARACTERISTICS:
- WHO performance status 0-1
- Hemoglobin ≥ 10 g/dL
- Absolute neutrophil count ≥ 1,500/mm³
- Thrombocyte count ≥ 100,000/mm³
- Bilirubin ≤ 1.5 times upper limit of normal (ULN)
- ALT ≤ 2.5 times ULN (5 times ULN if liver metastases present)
- Alkaline phosphatase ≤ 2.5 times ULN (5 times ULN if bone metastases present)
- Quick ≥ 70% OR INR ≤ 1.5
- Creatinine ≤ 2.0 times ULN
- Proteinuria ≤ 2+ by urine dipstick
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 12 months after completion of study treatment
- Able to understand trial information given by the investigator and complete quality of life questionnaire
- No pre-existing condition that would preclude swallowing and/or absorption of oral medication
No prior or concurrent malignancies, except for the following:
- Malignancy for which the minimum relapse-free interval is ≥ 5 years
- Nonmelanoma skin cancer or adequately treated carcinoma in situ of the cervix
No other medical condition that would preclude study participation, including any of the following:
- Unstable or uncompensated respiratory, cardiac, hepatic, or renal disease
- Active infection
- Uncontrolled diabetes mellitus
- Hypertension ≥ 150/100 mm Hg despite treatment
- Myocardial infarction within the past 3 months
- History of hemorrhagic disorders
- Non-healing wound, ulcer, or bone fracture
- No clinical history of coagulopathy or thrombosis
- No hemoptysis or hematemesis ≥ grade 2 (defined as bright red blood of ≥ 5 mL per episode) within the past 6 months
- No known hypersensitivity to study drug(s) or to any other component of the study drugs
- No significant traumatic injury within the past 28 days
- No serious underlying medical condition that would impair the ability of the patient to participate in the trial or that would preclude use of study drugs
- No cerebrovascular accident or other CNS bleeding within the past 6 months
PRIOR CONCURRENT THERAPY:
At least 4 weeks since prior radiotherapy and recovered
- No prior radiotherapy to lesion(s) selected for measurement
No prior chemotherapy for advanced disease
- At least 6 months since prior neoadjuvant or adjuvant systemic chemotherapy for NSCLC
- Prior intrapleural or intrapericardial local chemotherapy allowed
- No prior endothelial growth factor and/or vascular endothelial growth factor (receptor)-targeted therapy for NSCLC
- More than 28 days since prior major surgical procedure or open biopsy
- More than 30 days since prior treatment in another clinical trial
- No concurrent anticoagulants (e.g., phenprocoumon, acenocoumarol, or full-dose warfarin or heparin)
- No concurrent full-dose continuous use of non-steroid anti-inflammatory drugs (NSAIDs)
No concurrent aspirin or clopidogrel bisulfate
- Low-dose aspirin (≤ 325 mg daily) may be continued in patients at high risk for arterial thromboembolic disease
- No other concurrent drugs contraindicated for use with the study drugs, according to the Swissmedic-approved product information
- No other concurrent experimental drugs or anticancer therapy, including chemotherapy, immunotherapy, or hormone therapy
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Disease stabilization (DS) (complete response [CR], partial response [PR], or stable disease [SD]) as assessed by RECIST criteria after 12 weeks of treatment with bevacizumab and erlotinib hydrochloride
Time Frame: 12 weeks
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
DS as assessed by RECIST criteria after 6 and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride
Time Frame: 6 and 18 weeks
|
6 and 18 weeks
|
Objective response (CR or PR) as assessed by RECIST criteria after 6, 12, and 18 weeks of treatment with bevacizumab and erlotinib hydrochloride
Time Frame: 6, 12 and 18 weeks
|
6, 12 and 18 weeks
|
Best overall response when treated with bevacizumab and erlotinib hydrochloride
Time Frame: Until treatment ends
|
Until treatment ends
|
Adverse events (AEs) when treated with bevacizumab and erlotinib hydrochloride
Time Frame: Until treatment ends
|
Until treatment ends
|
Time to progression (TTP) when treated with bevacizumab and erlotinib hydrochloride
Time Frame: Until treatment ends
|
Until treatment ends
|
Time to treatment failure (TTF) when treated with bevacizumab and erlotinib hydrochloride
Time Frame: Until treatment ends
|
Until treatment ends
|
Quality of life (QOL) when treated with bevacizumab and erlotinib hydrochloride
Time Frame: Until treatment ends
|
Until treatment ends
|
Objective response (CR or PR) when treated with chemotherapy
Time Frame: Until treatment ends
|
Until treatment ends
|
Unexpected adverse drug reaction
Time Frame: Until treatment ends
|
Until treatment ends
|
QOL when treated with chemotherapy
Time Frame: Periodically
|
Periodically
|
Overall survival (OS) in patients treated with bevacizumab and erlotinib hydrochloride and in patients treated with subsequent chemotherapy at disease progression
Time Frame: life-long
|
life-long
|
Collaborators and Investigators
Investigators
- Study Chair: Francesco Zappa, MD, Istituto Oncologico della Svizzera Italiana - Ospedale San Giovanni
Publications and helpful links
General Publications
- Zappa F, Droege C, Betticher D, von Moos R, Bubendorf L, Ochsenbein A, Gautschi O, Oppliger Leibundgut E, Froesch P, Stahel R, Hess T, Rauch D, Schmid P, Mayer M, Crowe S, Brauchli P, Ribi K, Pless M; Swiss Group for Clinical Cancer Research (SAKK). Bevacizumab and erlotinib (BE) first-line therapy in advanced non-squamous non-small-cell lung cancer (NSCLC) (stage IIIB/IV) followed by platinum-based chemotherapy (CT) at disease progression: a multicenter phase II trial (SAKK 19/05). Lung Cancer. 2012 Dec;78(3):239-44. doi: 10.1016/j.lungcan.2012.08.017. Epub 2012 Sep 23.
- Baty F, Joerger M, Fruh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. J Transl Med. 2017 Mar 30;15(1):66. doi: 10.1186/s12967-017-1174-z.
- Franzini A, Baty F, Macovei II, Durr O, Droege C, Betticher D, Grigoriu BD, Klingbiel D, Zappa F, Brutsche MH. Gene Expression Signatures Predictive of Bevacizumab/Erlotinib Therapeutic Benefit in Advanced Nonsquamous Non-Small Cell Lung Cancer Patients (SAKK 19/05 trial). Clin Cancer Res. 2015 Dec 1;21(23):5253-63. doi: 10.1158/1078-0432.CCR-14-3135. Epub 2015 Apr 28.
- Joerger M, Baty F, Fruh M, Droege C, Stahel RA, Betticher DC, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). Lung Cancer. 2014 Aug;85(2):306-13. doi: 10.1016/j.lungcan.2014.04.014. Epub 2014 May 29.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Respiratory Tract Diseases
- Neoplasms
- Lung Diseases
- Neoplasms by Site
- Respiratory Tract Neoplasms
- Thoracic Neoplasms
- Lung Neoplasms
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Anti-Infective Agents
- Antiviral Agents
- Enzyme Inhibitors
- Antimetabolites, Antineoplastic
- Antimetabolites
- Antineoplastic Agents
- Immunosuppressive Agents
- Immunologic Factors
- Antineoplastic Agents, Immunological
- Angiogenesis Inhibitors
- Angiogenesis Modulating Agents
- Growth Substances
- Growth Inhibitors
- Protein Kinase Inhibitors
- Gemcitabine
- Carboplatin
- Erlotinib Hydrochloride
- Bevacizumab
Other Study ID Numbers
- SAKK 19/05
- EU-20614
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
M.D. Anderson Cancer CenterRecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage... and other conditionsUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer... and other conditionsUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
Dana-Farber Cancer InstituteMedWaves, IncNot yet recruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung CancerUnited States
-
City of Hope Medical CenterNational Cancer Institute (NCI)Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7United States
-
WindMIL TherapeuticsBristol-Myers SquibbTerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer MetastaticUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI); Genentech, Inc.RecruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung... and other conditionsUnited States
-
Emory UniversityNational Cancer Institute (NCI)TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
University of California, San FranciscoMerck Sharp & Dohme LLCWithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer...United States
-
City of Hope Medical CenterNational Cancer Institute (NCI)CompletedStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Metastatic Lung Carcinoma | Stage IV Lung Cancer AJCC v8 | Head and Neck Carcinoma | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung... and other conditionsUnited States
Clinical Trials on bevacizumab + erlotinib hydrochloride
-
Northwestern UniversityM.D. Anderson Cancer CenterCompletedBrain and Central Nervous System TumorsUnited States
-
Southwest Oncology GroupNational Cancer Institute (NCI)CompletedLung CancerUnited States
-
University of UtahGenentech, Inc.Completed
-
Southwest Oncology GroupNational Cancer Institute (NCI)Completed
-
Medical University of South CarolinaCompletedLiver CancerUnited States
-
National Cancer Center, KoreaRoche Korea co.,Ltd.Active, not recruitingEGFR Positive Non-small Cell Lung CancerKorea, Republic of
-
GERCOR - Multidisciplinary Oncology Cooperative...Completed
-
Swiss Group for Clinical Cancer ResearchCompleted
-
National Taiwan University HospitalUnknownCarcinoma, Non-Small-Cell Lung | Brain NeoplasmsTaiwan
-
Hunan Province Tumor HospitalRecruitingNon Small Cell Lung CancerChina